Genetic Engineering & Biotechnology News

DEC 2018

Genetic Engineering & Biotechnology News (GEN) is the world's most widely read biotech publication. It provides the R&D community with critical information on the tools, technologies, and trends that drive the biotech industry.

Issue link:

Contents of this Issue


Page 15 of 57

Antibodies and Antibody- Drug Conjugate Higher Order Structures Revealed Recently investigators have begun to harness new technology such as microuidic modulation spectroscopy (MMS) to reveal protein structural changes, as a solid understanding of structure and function is extremely important to the eectiveness of biotherapeutic drugs and scientist today are challenged in gathering a complete understanding with current tools During the biomanufacturing process, proteins such as antibodies, often undergo conformational changes that can alter their secondary structure, leading to critical variations in their overall function. These changes have been historically di•cult to detect, as traditional analytical techniques are not great at detecting small dierences in protein structure. MMS however, can detect these changes with great sensitivity and accuracy without the need for dilution or chemical alteration. Moreover, MMS oers detailed information on which structural motifs in the protein molecule are changing, providing more guidance to scientists in their eorts to develop more stable antibody molecules and formulations. Join us for this new GEN webinar where we will learn how MMS technology is making a signiƒcant impact toward understanding the structures of therapeutic antibodies and antibody drug conjugates. Presentation Highlights: • Characterization of mAb's and ADC's without the need for dilutions or concern for your formulation buer's excipient interferences, enabled by MMS, is critical to understand the TRUE structure of your drug product at the intended therapeutic conditions. • Microuidic Modulation Spectroscopy provides a reliable platform with increased sensitive and higher resolution for secondary structure analysis of biotherapeutics. • MMS's Automated walk away workow makes it applicable for screening studies much earlier in the development process A live Q&A session will follow the presentation, oering you a chance to pose questions to our expert panelists. Free Registration! View It Now! On Demand DURATION: 60 minutes COST: Complimentary Speakers Karan Shah Principal Development Associate, ImmunoGen Ioannis Papayannopoulos, Ph.D. Senior Scientist III, Celldex Therapeutics Eugene Ma, Ph.D. Chief Technical O•cer, RedShift BioAnalytics Produced with support from Webinars

Articles in this issue

Links on this page

Archives of this issue

view archives of Genetic Engineering & Biotechnology News - DEC 2018